ALUR vs. TELA, EDAP, MLSS, MDAI, SURG, HYPR, NEPH, ICCM, APT, and CTCX
Should you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include TELA Bio (TELA), EDAP TMS (EDAP), Milestone Scientific (MLSS), Spectral AI (MDAI), SurgePays (SURG), Hyperfine (HYPR), Nephros (NEPH), IceCure Medical (ICCM), Alpha Pro Tech (APT), and Carmell (CTCX). These companies are all part of the "medical equipment" industry.
Allurion Technologies vs. Its Competitors
TELA Bio (NASDAQ:TELA) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.
Allurion Technologies has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
TELA Bio has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500.
TELA Bio presently has a consensus target price of $7.25, suggesting a potential upside of 279.58%. Allurion Technologies has a consensus target price of $22.83, suggesting a potential upside of 791.93%. Given Allurion Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Allurion Technologies is more favorable than TELA Bio.
TELA Bio has a net margin of -61.00% compared to Allurion Technologies' net margin of -86.05%. Allurion Technologies' return on equity of 0.00% beat TELA Bio's return on equity.
94.4% of TELA Bio shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 4.7% of TELA Bio shares are held by company insiders. Comparatively, 22.4% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, TELA Bio and TELA Bio both had 1 articles in the media. TELA Bio's average media sentiment score of 1.87 beat Allurion Technologies' score of 0.00 indicating that TELA Bio is being referred to more favorably in the media.
Summary
TELA Bio and Allurion Technologies tied by winning 8 of the 16 factors compared between the two stocks.
Get Allurion Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allurion Technologies Competitors List
Related Companies and Tools
This page (NYSE:ALUR) was last updated on 7/3/2025 by MarketBeat.com Staff
